Bioqual (BIOQ) Stock Price

Bioqual Price

NYSE·CLOSED
32.50USD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 5.6% per year over the past 32 years to 48.87 M USD. Earnings per share have grown at 1.3% per year over the last 31 years. Bioqual's net margin stands at -2.1%, down from 11.0% several years earlier. Bioqual currently offers a dividend yield of about 1.54%. The payout ratio is around 54% of earnings. The dividend has grown at 3.6% per year over the past 10 years.

Bioqual stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Bioqual over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bioqual stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bioqual's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bioqual Stock Price History
DateBioqual Price
7/9/202632.50 USD
7/8/202632.50 USD
7/7/202632.50 USD
7/6/202632.50 USD
7/2/202632.50 USD
7/1/202632.50 USD
6/30/202632.50 USD
6/29/202632.50 USD
6/26/202632.50 USD
6/25/202632.50 USD
6/24/202632.50 USD
6/23/202632.50 USD
6/22/202632.50 USD
6/18/202632.50 USD
6/17/202632.50 USD
6/16/202632.50 USD
6/15/202632.50 USD
6/12/202632.50 USD
6/11/202632.50 USD
6/10/202632.50 USD
6/9/202632.50 USD
6/8/202632.50 USD
6/5/202632.50 USD
6/4/202632.50 USD
6/3/202632.50 USD
6/2/202632.50 USD
6/1/202632.50 USD
5/29/202632.50 USD
5/28/202635.00 USD
5/27/202635.00 USD
5/26/202635.01 USD
5/22/202635.01 USD
5/21/202635.01 USD
5/20/202635.01 USD
5/19/202635.01 USD
5/18/202635.01 USD
5/15/202635.20 USD
5/14/202635.20 USD
5/13/202635.20 USD
5/12/202635.20 USD
5/11/202635.20 USD
5/8/202635.20 USD
5/7/202635.20 USD
5/6/202637.51 USD
5/5/202637.51 USD
5/4/202637.51 USD
5/1/202637.51 USD
4/30/202637.51 USD
4/29/202637.51 USD
4/28/202637.51 USD
4/27/202637.51 USD
4/24/202637.51 USD
4/23/202637.51 USD
4/22/202637.51 USD
4/21/202637.51 USD
4/20/202637.51 USD
4/17/202637.51 USD
4/16/202637.51 USD
4/15/202637.51 USD
4/14/202637.51 USD
4/13/202637.51 USD
4/10/202637.51 USD
4/9/202637.51 USD
4/8/202637.51 USD
4/7/202637.51 USD
4/6/202637.51 USD
4/2/202637.51 USD
4/1/202637.51 USD
3/31/202637.51 USD
3/30/202637.51 USD
3/27/202637.51 USD
3/26/202637.51 USD
3/25/202637.51 USD
3/24/202637.51 USD
3/23/202637.51 USD
3/20/202637.51 USD
3/19/202637.51 USD
3/18/202637.51 USD
3/17/202637.51 USD
3/16/202637.51 USD
3/13/202637.51 USD
3/12/202637.51 USD
3/11/202637.51 USD
3/10/202637.51 USD
3/9/202637.51 USD
3/6/202637.51 USD
3/5/202637.51 USD
3/4/202637.51 USD
3/3/202637.51 USD
3/2/202637.51 USD
2/27/202637.51 USD
2/26/202637.51 USD
2/25/202637.51 USD
2/24/202637.51 USD
2/23/202637.51 USD
2/20/202637.51 USD
2/19/202637.51 USD
2/18/202637.51 USD
2/17/202637.51 USD
2/13/202637.51 USD
2/12/202637.51 USD
2/11/202637.51 USD
2/10/202637.51 USD
2/9/202637.51 USD
2/6/202637.51 USD
2/5/202637.70 USD
2/4/202637.70 USD
2/3/202637.70 USD
2/2/202637.70 USD
1/30/202637.70 USD
1/29/202637.70 USD
1/28/202638.50 USD
1/27/202638.50 USD
1/26/202638.50 USD
1/23/202638.50 USD
1/22/202638.50 USD
1/21/202638.50 USD
1/20/202638.50 USD
1/16/202638.50 USD
1/15/202638.50 USD
1/14/202638.50 USD
1/13/202638.50 USD
1/12/202638.50 USD
1/9/202638.50 USD
1/8/202638.50 USD
1/7/202638.50 USD
1/6/202638.50 USD
1/5/202638.51 USD
1/2/202638.51 USD
12/31/202538.51 USD
12/30/202538.51 USD
12/29/202538.51 USD
12/26/202538.51 USD
12/24/202538.51 USD
12/23/202538.51 USD
12/22/202538.51 USD
12/19/202538.51 USD
12/18/202538.51 USD
12/17/202538.51 USD
12/16/202538.51 USD
12/15/202538.51 USD
12/12/202538.51 USD
12/11/202538.51 USD
12/10/202538.51 USD
12/9/202538.51 USD
12/8/202538.51 USD
12/5/202538.51 USD
12/4/202538.51 USD
12/3/202538.51 USD
12/2/202538.51 USD
12/1/202538.51 USD
11/28/202538.51 USD
11/26/202538.51 USD
11/25/202538.51 USD
11/24/202538.51 USD
11/21/202538.51 USD
11/20/202538.51 USD
11/19/202538.51 USD
11/18/202538.51 USD
11/17/202538.51 USD
11/14/202538.51 USD
11/13/202538.51 USD
11/12/202538.51 USD
11/11/202538.51 USD
11/10/202538.51 USD
11/7/202540.00 USD
11/6/202540.00 USD
11/5/202540.00 USD
11/4/202540.00 USD
11/3/202540.00 USD
10/31/202540.00 USD
10/30/202540.00 USD
10/29/202540.00 USD
10/28/202540.00 USD
10/27/202540.00 USD
10/24/202540.00 USD
10/23/202540.00 USD
10/22/202540.00 USD
10/21/202540.00 USD
10/20/202540.00 USD
10/17/202540.00 USD
10/16/202540.00 USD
10/15/202540.00 USD
10/14/202540.00 USD
10/13/202540.00 USD
10/10/202540.00 USD
10/9/202540.00 USD
10/8/202540.00 USD
10/7/202540.00 USD
10/6/202540.00 USD
10/3/202540.00 USD
10/2/202540.00 USD
10/1/202540.00 USD
9/30/202540.00 USD
9/29/202540.00 USD
9/26/202540.00 USD
9/25/202540.00 USD
9/24/202540.00 USD
9/23/202540.00 USD
9/22/202537.00 USD
9/19/202537.00 USD
9/18/202539.00 USD
9/17/202539.00 USD
9/16/202539.00 USD
9/15/202540.01 USD
9/12/202540.01 USD
9/11/202540.01 USD
9/10/202543.55 USD
9/9/202543.55 USD
9/8/202543.55 USD
9/5/202543.19 USD
9/4/202543.19 USD
9/3/202543.19 USD
9/2/202543.19 USD
8/29/202543.19 USD
8/28/202543.19 USD
8/27/202543.19 USD
8/26/202543.19 USD
8/25/202543.19 USD
8/22/202543.19 USD
8/21/202543.19 USD
8/20/202543.19 USD
8/19/202543.19 USD
8/18/202543.19 USD
8/15/202543.19 USD
8/14/202543.19 USD
8/13/202543.19 USD
8/12/202543.19 USD
8/11/202543.19 USD
8/8/202543.19 USD
8/7/202543.19 USD
8/6/202543.19 USD
8/5/202543.19 USD
8/4/202543.19 USD
8/1/202543.19 USD
7/31/202543.19 USD
7/30/202543.19 USD
7/29/202543.19 USD
7/28/202543.19 USD
7/25/202543.19 USD
7/24/202543.19 USD
7/23/202543.19 USD
7/22/202543.19 USD
7/21/202543.19 USD
7/18/202543.19 USD
7/17/202543.19 USD
7/16/202543.19 USD
7/15/202543.19 USD
7/14/202543.19 USD
Access this data via the Eulerpool API

Bioqual Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
35.89 M USD
5.27 M USD
3.66 M USD
Jan 1, 2019
39.48 M USD
3.58 M USD
2.83 M USD
Jan 1, 2020
46.36 M USD
5.32 M USD
4.23 M USD
Jan 1, 2021
57.68 M USD
8.56 M USD
6.33 M USD
Jan 1, 2022
66.15 M USD
6.53 M USD
5.26 M USD
Jan 1, 2023
62.66 M USD
1.10 M USD
835,600.00 USD
Jan 1, 2024
58.59 M USD
-19,600.00 USD
483,500.00 USD
Jan 1, 2025
48.87 M USD
-1.90 M USD
-1.05 M USD

Bioqual Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 10:08 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
NET INCOMEM USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
1997199819992000200120152016201720182019202020212022202320242025
8.009.0011.0011.0012.0028.0033.0036.0035.0039.0046.0057.0066.0062.0058.0048.00
12.5022.229.09133.3317.869.09-2.7811.4317.9523.9115.79-6.06-6.45-17.24
25.0022.2218.1818.1816.6721.4321.2125.0022.8617.9519.5722.8119.7012.9012.078.33
2.002.002.002.002.006.007.009.008.007.009.0013.0013.008.007.004.00
1.002.003.003.002.004.006.005.00-1.00
100.0050.00-33.33100.0050.00-16.67
0.350.600.701.101.250.500.500.50
16.6757.1413.64
0.910.900.900.880.890.890.890.890.890.890.890.890.890.890.890.89
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bioqual generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bioqual retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bioqual's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bioqual has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bioqual's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bioqual stock margins

The Bioqual margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bioqual. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bioqual.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
24.31 %
14.69 %
10.21 %
Jan 1, 2019
18.77 %
9.08 %
7.17 %
Jan 1, 2020
20.90 %
11.48 %
9.13 %
Jan 1, 2021
24.23 %
14.83 %
10.97 %
Jan 1, 2022
19.66 %
9.88 %
7.95 %
Jan 1, 2023
13.80 %
1.76 %
1.33 %
Jan 1, 2024
12.68 %
-0.03 %
0.83 %
Jan 1, 2025
9.05 %
-3.88 %
-2.14 %

Bioqual Stock Revenue, EBIT, Earnings per Share

The Bioqual earnings per share therefore indicates how much revenue Bioqual has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
40.16 USD
5.90 USD
4.10 USD
Jan 1, 2019
44.17 USD
4.01 USD
3.17 USD
Jan 1, 2020
51.86 USD
5.95 USD
4.73 USD
Jan 1, 2021
64.52 USD
9.57 USD
7.08 USD
Jan 1, 2022
73.96 USD
7.30 USD
5.88 USD
Jan 1, 2023
70.06 USD
1.23 USD
0.93 USD
Jan 1, 2024
65.51 USD
-0.02 USD
0.54 USD
Jan 1, 2025
54.64 USD
-2.12 USD
-1.17 USD

Bioqual business model & stock analysis

Bioqual Inc. is an emerging biotechnology company based in Maryland, USA. The company was founded in 1988 with the aim of developing innovative solutions and services for the life sciences and pharmaceutical industry. The founding of Bioqual is closely connected to the emergence of new technologies in the field of biotechnology and genomics research. The company has always been committed to developing innovative products and services that contribute to improving the diagnosis and treatment of diseases, accelerating or facilitating the development of new drugs, and enhancing the quality of animal testing. In its early years, Bioqual primarily focused on the development of diagnostic test systems for animal diseases. In the 1990s, the company expanded its scope to research on infectious diseases and vaccine development. Since 2000, Bioqual has shifted its focus to drug discovery and preclinical studies. Today, Bioqual offers a wide range of products and services in various areas. These include immunological assays, cell culture and microbiology laboratory services, preclinical studies and animal testing services, as well as support in the development of new drugs. An important business model of Bioqual is collaboration with other companies. The company is a key partner for biotech and pharmaceutical companies involved in the development of new drugs and therapies. Bioqual offers preclinical studies and animal testing services to test the effectiveness and safety of new drugs. Partner companies can thus pool their resources and accelerate the testing phase. Bioqual also has its own research and development department and collaborates with academic and medical institutions in the development of new diagnostic and therapeutic methods. Another important area for Bioqual is animal testing services. The company offers specialized animal testing services, including the creation of animal models, conducting studies on the efficacy, pharmacokinetics, and toxicity of substances, as well as regulatory consulting services. In recent years, Bioqual has expanded its presence in the field of diagnostics and treatment of infectious diseases. The company offers serological assays and PCR tests to diagnose infections caused by viruses, bacteria, and parasites. Additionally, Bioqual is involved in the development of vaccines against a variety of infectious diseases, including HIV, Hepatitis C, Zika, and West Nile Virus. The products and services of Bioqual are applied in various areas of life sciences and medicine. They are utilized by pharmaceutical and biotech companies, government agencies, academic institutions, and medical laboratories. Bioqual has shown strong growth in recent years. The company continuously invests in research and development of new products and services to meet the needs of its customers. The company also has a strong presence in various global markets, particularly in Europe, Asia, and South America. Bioqual has established a reputation as an innovative and reliable company in the biotechnology and pharmaceutical industry. With its wide range of products and services and close collaboration with other companies, Bioqual positions itself as a key partner in the development of new diagnostic and therapeutic methods, as well as the exploration of infectious diseases and new drugs.

Bioqual SWOT Analysis

Strengths

1. Established reputation in the industry for scientific research and experimentation.

2. Extensive expertise in conducting pre-clinical research studies.

3. Strong network of partnerships with leading pharmaceutical and biotech companies.

Weaknesses

1. Relatively small team of expert researchers, which may limit the number of projects the company can undertake simultaneously.

2. Limited financial resources, potentially hindering investment in new technologies and equipment.

3. Dependence on a few major clients for a significant portion of revenue, posing a risk if any of these clients reduce their contracts.

Opportunities

1. Growing demand for pre-clinical research services in the healthcare industry.

2. Advancements in technology that can enhance research capabilities and attract more clients.

3. Expansion into emerging markets with less competition and potential for strategic partnerships.

Threats

1. Intense competition from larger and well-established research organizations.

2. Strict regulatory environment and increasing compliance requirements in the industry.

3. Economic downturns affecting funding for research and development projects.

Bioqual Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bioqual historical P/E ratio, EBIT multiple, and P/S ratio

Bioqual annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bioqual shares outstanding

The number of shares of Bioqual was 894,400 in 2025. This indicates how many shares Bioqual is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
893,500.00 Stocks
Jan 1, 2019
893,700.00 Stocks
Jan 1, 2020
894,000.00 Stocks
Jan 1, 2021
894,100.00 Stocks
Jan 1, 2022
894,400.00 Stocks
Jan 1, 2023
894,400.00 Stocks
Jan 1, 2024
894,400.00 Stocks
Jan 1, 2025
894,400.00 Stocks

Bioqual Dividend History

19 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.50USD 0.0%
20240.50USD 0.0%
20230.50USD 50.0%
20221.00USD 20.0%
20211.25USD 13.6%
20201.10USD 57.1%
20190.70USD 16.7%
20180.60USD 0.0%
20170.60USD 33.3%
20160.45USD 28.6%

Bioqual dividend history and estimates

In 2025, Bioqual paid a dividend amounting to 0.50 USD. Dividend means that Bioqual distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2018
0.60 USD
0.00 USD
0.00 USD
Jan 1, 2019 (e)
0.00 USD
0.70 USD
0.00 USD
Jan 1, 2020
1.10 USD
0.00 USD
0.00 USD
Jan 1, 2021
1.25 USD
0.00 USD
0.00 USD
Jan 1, 2022 (e)
1.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.50 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.50 USD
0.00 USD
0.20 USD
Jan 1, 2025
0.50 USD
0.00 USD
0.35 USD

Bioqual dividend payout ratio

In 2025, Bioqual had a payout ratio of 54.34%. The payout ratio indicates the percentage of the company's profits that Bioqual distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
54.34 %
Jan 1, 2019
22.15 %
Jan 1, 2020
23.24 %
Jan 1, 2021
17.66 %
Jan 1, 2022
17.00 %
Jan 1, 2023
53.52 %
Jan 1, 2024
92.49 %
Jan 1, 2025
54.34 %
Price targets and forecasts for Bioqual are not yet available.

Bioqual shareholder structure

% Name
0.00000%
BIP Wealth, LLC
BIP Wealth, LLC

Bioqual Executives and Management Board

DN

Mr. David Newcomer

(48)

Director · since 1989

Compensation123,785.00 USD
ML

Mr. Mark Lewis

Chairman of the Board · since 2015

HE

Dr. Hanne Elyard

President, Chief Executive Officer

CK

Mr. Charles Kirk

Chief Financial Officer

MF

MITCH FRANKLIN

Vice President - Operations

Frequently asked questions about Bioqual

The business model of Bioqual Inc is to provide contract research services to biotechnology and pharmaceutical companies, government agencies, and academic institutions. Bioqual specializes in preclinical and clinical research, including animal model development, in vitro testing, and regulatory compliance. Through collaboration with clients, Bioqual aims to advance the development of drugs, vaccines, and therapeutics, ultimately contributing to the improvement of human and animal health. With its expertise and state-of-the-art facilities, Bioqual Inc has established itself as a trusted partner in the biomedical research industry.

All fundamentals and in-depth analysis of Bioqual

Our stock analysis for Bioqual stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioqual. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.